Ben Hargreaves speaks to Liberate Bio, a company that is hoping to address the delivery issues that could prevent mRNA, as well as siRNA and ASO therapeutics, from reaching their full potential ...

These findings will fuel future work to develop nanoparticles containing therapeutic mRNA and siRNA as researchers study their effects in clinically translatable animal models. "We can use our ...

run experiments with different siRNA concentrations to determine the level of knockdown you need to see a change in phenotype, Behlke says. Optimize for each cell type. "The efficiency of siRNAs to ...

RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with ...

In a new study, researchers demonstrate that exosomes can serve as delivery vehicles to introduce AGO2-loaded siRNA into the cytoplasm of bacteria which downregulate gene expression of the mRNA ...

Problem: siRNA might depress mRNA levels but not induce the expected phenotype. Controls: Looking for a decrease in levels of your targeted mRNA isn't enough, Rozenfeld says; you should also look for ...

Discover how RNA therapeutics are reshaping medicine, offering new treatments for previously undruggable targets.

Nanoparticles are a promising vector-based strategy for the therapeutic administration of small interfering (si)RNA because they protect siRNA from nuclease degradation. A recent phase I study ...

The firm said its next-generation siRNA candidate showed in preclinical studies that it could reduce tumor growth and metastatic spread.

Even though the delivered siRNA was designed for possessing full sequence complementarity to the bacterial mRNA, downregulation of the target protein was achieved at the translational level rather ...